Overview

Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

Status:
Completed

Trial end date:
2005-12-01

Target enrollment:

Participant gender:

Summary

Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen
Celgene Corporation

Treatments:

Apremilast